Objective: To explore the association of urinary N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations and closure of patent ductus arteriosus (PDA) in preterm infants.
Introduction
Patent ductus arteriosus (PDA) in preterm infants can have significant clinical consequences when pulmonary vascular resistance decreases continuously during the first days and weeks of birth. 1, 2 This leads to the augmentation of the left-to-right shunt through the PDA, thereby increasing pulmonary blood flow that results in pulmonary edema and increased cardiac preload. PDA has been associated with various diseases in preterm newborn infants, including bronchopulmonary dysplasia, necrotizing enterocolitis and retinopathy of prematurity. It is, however, unclear whether and when a conservative, pharmacological or surgical approach for PDA closure may be most advantageous. 3, 4 Although echocardiography is the gold standard for diagnosis, it is not always readily available in the Neonatal Intensive Care Units. 5, 6 Recent studies have shown that blood concentrations of natriuretic peptides secreted by the heart are useful in the diagnosis of hemodynamically significant PDA (hsPDA). [7] [8] [9] [10] Plasma levels of brain natriuretic peptide (BNP) and its N-terminal precursor, Nterminal pro-brain natriuretic peptide (NT-proBNP), are highly sensitive markers in predicting whether a clinician provided with clinical and echocardiographic informations would decide to treat a PDA and can also be useful in guiding pharmacological therapy. [11] [12] [13] [14] [15] [16] The majority of studies on the diagnostic potential of natriuretic peptides in PDA have been performed on plasma samples. Assessment of the concentration of NT-proBNP in urine may, however, be useful in certain circumstances, especially in preterm infants where urine sampling is readily accessible and non-invasive. Previous studies on the presence of NT-proBNP in urine and its clinical significance have been limited to adult patients. 17, 18 We hypothesized that elevated concentrations of urinary NT-proBNP in preterm infants are related to the need for ventilatory support and PDA intervention. The aims of this study were to analyze the presence of NT-proBNP in urine of preterm infants, to correlate NT-proBNP urine levels with a need for PDA intervention and then use these results to investigate the potential diagnostic and prognostic value of urinary NT-proBNP in preterm infants.
Methods
A prospective longitudinal study was conducted at a single tertiary care perinatal center from August 2008 to December 2009. The study protocol was approved by the local institutional review board (Ethikkommission der Charité, no. EA2/072/08). After written informed parental consent, preterm inborn infants born below <32 weeks gestational age and <1500 g birth weight were included. Infants who had a congenital heart malformation or infants who died in the first month of life were excluded. The study population is shown in Figure 1 . Neonatal and post-neonatal outcome data recorded were gestational age, birth weight, gender, antenatal steroid course complete (2 Â 12 mg betamethasone more than 24 h before delivery), occurrence and grade of necrotizing enterocolitis, intraventricular hemorrhage, periventricular leukomalacia and death beyond 1 month of life before discharge.
Urine sampling and measurement of urinary NT-proBNP Urine was collected in plastic bags on day of life (DOL) 2, 7, 14 and 28. The samples (1 ml) were spun at 7000 r.p.m. for 3 min. Cell-free urine was stored at À80 1C until NT-proBNP concentrations were determined using a commercially available electrochemiluminescent sandwich immunoassay (proBNP II; Roche Diagnostics, Mannheim, Germany) on a cobas e 411 analyzer (Roche Diagnostics). The NT-proBNP measuring range in the serum or plasma, as reported by the manufacturer, was 5 to 35 000 pg ml À1 , with a total coefficient of variation of 1.6 to 4.6%. Samples above the measuring range were reassessed after dilution with a diluent assigned by the manufacturer.
Before measuring clinical samples, the adequacy of this assay to measure NT-proBNP in urine had been validated as described previously. 19 To account for possible differences in urine concentrations, creatinine concentrations were also determined in the same samples. We then calculated the NT-proBNP/creatinine ratios. All NT-proBNP results were withheld by the laboratory until close of recruitment in December 2009 to ensure that clinical investigators were blinded to the NT-proBNP results.
Echocardiography
Real-time two-dimensional color Doppler echocardiography (7S probe (3.5 to 6.9 MHz), Vivid 7 Dimension'06; GE Vingmed, Horten, Norway) was performed between 24 and 48 h after birth and on DOL 7, 14 and 28 by two experienced echocardiographers. At least three consecutive cardiac cycles were recorded for the measurements and the mean values were used. All measurements were performed by the same two investigators independently so that the inter-observer variability could be analyzed. The diameter of the ductus arteriosus was measured using two-dimensional echo images obtained from the high left parasternal short-axis view. The left atrial/aorta ratio was determined in the parasternal long axis with M-mode according to the leading-edge method recommended by the American Society of Echocardiography. 20 Neonates without indication for ductus intervention at DOL 2, 7, 14 and 28, who were later clinically suspected of having a significant PDA, for example, need for ventilatory support, received additional echocardiographic evaluation.
Criteria for ductus intervention PDA intervention was indicated based on the presence of the following previously established criteria: 21 PDA with left-to-right shunt, narrowest diameter >2 mm plus the need for invasive ventilatory support.
Management of PDA
Infants who fulfilled our PDA intervention criteria received indomethacin or ibuprofen unless contraindicated. The initial dose regimen for indomethacin was 0.2 mg kg À1 intravenously, followed by two additional doses of 0.2 mg kg À1 at 12-h intervals and three additional doses of 0.1 mg kg À1 at 24-h intervals. Ibuprofen was administered intravenously at 10 mg kg À1 , followed by two additional doses of 5 mg kg À1 at 24-h intervals. Clinical and echocardiographic PDA assessment was performed after the initial course of indomethacin or ibuprofen. If the criteria for PDA intervention were met again, a second course of indomethacin or ibuprofen was administered. Surgical closure was performed when indomethacin or ibuprofen was contraindicated or the PDA remained open despite two attempts at pharmacological closure.
Statistical analysis Patient characteristics were described by rates (%) or median values and quartiles and compared using Fisher's exact test or the Mann-Whitney U-test as appropriate. The NT-proBNP/creatinine ratios were presented as the median and interquartile range and compared using the Mann-Whitney U-test. Inter-and intraobserver variability of the ductal diameter measurements was calculated from 55 consecutive patients. The coefficient of variation of consecutively measured cycles was used to describe the intraobserver variability by median and quartiles. The intra-observer variability was calculated for both investigators and compared using the Wilcoxon test. A Bland-Altman analysis and intraclass correlation coefficient were performed to describe inter-observer variability. 22 Spearman's rank order correlation coefficients were calculated to investigate the impact of echocardiographic parameters on the NT-proBNP/creatinine ratio at the four measurement time points. The predictive value of NT-proBNP/ creatinine ratios for pharmacological non-responsiveness was estimated by the areas under receiver operating characteristic curves, which were also used to determine the optimal cutoff. Applying this cutoff, we then calculated positive and negative Urinary NT-proBNP and PDA C Czernik et al predictive values, sensitivities and specificities. Forward, stepwise logistic regression analyses were performed to assess whether variables were independent predictors for ductus intervention. Statistical analysis was performed using the SPSS 18 (IBM s ) and MedCalc software (Version 9.1.0.1; MedCalc Software, Mariakerke, Belgium). A P-value <0.05 was considered statistically significant.
Results
In all, 136 infants (73 male, 63 female) were eligible for analysis and had a median gestational age of 28 weeks (interquartile range 26 to 30) and median birth weight of 1030 g (interquartile range 780 to 1270). Of these, 125 (92%) infants had received a full course of antenatal betamethasone for fetal lung maturation. One infant each was diagnosed with severe intraventricular hemorrhage (grade 3 without subsequent shunt insertion), cystic periventricular leukomalacia and necrotizing enterocolitis, respectively. One infant died after 36 weeks gestational age but before discharge.
Of the 136 infants enrolled, 101 had no hsPDA. All 35 infants with hsPDA were treated with indomethacin or ibuprofen. There were no differences in age at the beginning of PDA treatment between the infants with pharmacological successful PDA closure (responders) and the infants who needed subsequent surgical duct ligation (non-responders). The pharmacological treatment success rate was 48% (17/35). All 18 non-responders had surgical ligation after DOL 14.
Reproducibility of ductal diameter measurements
The intra-observer variability for the ductal diameter of both observers was acceptable with a median (interquartile range) coefficient of variation of 5.7% (3.9 to 8.7%) for observer 1 and 6.6% (4.2 to 9.5%) for observer 2. There was no statistically significant difference between observer 1 and observer 2 (P ¼ 0.238), whereas there was a good agreement in the measured ductal diameter between the two investigators. Bland-Altman plots demonstrated a negligible systematic difference between the investigators (Figure 2 ). The intraclass correlation coefficient for the inter-observer variability was 0.955 (95% confidence interval, 0.925 to 0.974). Furthermore, the deviations between the investigators were randomly distributed.
Relationship between urinary NT-proBNP and echocardiographic parameters Table 1 shows the correlation of urinary NT-proBNP/creatinine ratios with echocardiographic parameters at the four time points of measurement in our study population. Urinary NT-proBNP/ creatinine ratios did not correlate with the left atrial/aorta ratio at DOL 2, but a statistically significant correlation emerged alongside increasing age. In contrast, there was a statistically significant correlation between NT-proBNP/creatinine ratios and ductal diameter at all measurement time points.
Urinary NT-proBNP
The highest urinary NT-proBNP/creatinine ratios were found on DOL 2 (median (interquartile range) 74 (17 to 248) mg g À1 ), followed by a sequential decline (DOL 7: 23 (5 to 77) mg g À1 ; DOL 14: 11 (3 to 55) mg g; DOL 28: 4 (2 to 12) mg g À1 ). Urinary NTproBNP/creatinine ratios did not differ between male and female infants (P>0.1). Table 2 provides the median and interquartile range of values for samples collected from the entire cohort of 136 infants at different time points according to the need for invasive ventilatory support, need for PDA intervention and response to successful pharmacological duct closure. Ventilated infants had higher urinary NT-proBNP/creatinine ratios than infants without invasive ventilatory support on DOL 2, 7 and 14. Infants with PDA intervention had higher urinary NT-proBNP/creatinine ratios on DOL 2 and 14 than ventilated infants without PDA intervention. This difference failed to attain a level of significance on DOL 7. Urinary NT-proBNP and PDA C Czernik et al
The variability in response to pharmacological treatment among those infants whose PDA failed to close and therefore needed a surgical ligation was explored further. On DOL 2, there was no difference in urinary NT-proBNP/creatinine ratios between responders and non-responders. On DOL 7, we saw a trend towards higher median urinary NT-proBNP/creatinine ratios in infants who were non-responsive to pharmacological treatment and required subsequent surgical ligation, although the difference was not significant. On DOL 14, in contrast, infants who failed to respond to pharmacological treatment had significantly higher median urinary NT-proBNP/creatinine ratios than infants in whom the duct closed or was small after the first or second course of pharmacological treatment (median 247 (214 to 547) vs 56 (21 to 114) mg g À1 ; P ¼ 0.04). With respect to successful pharmacological duct closure, on DOL 14 we found that a urinary NT-proBNP/creatinine ratio >210 mg g À1 predicted pharmacological non-responsiveness, with a sensitivity of 75%, a specificity of 100%, a positive predictive value of 100% and a negative predictive value of 63% (P ¼ 0.035; area under the curve ¼ 0.83; 95% confidence interval of 0.64 to 1.0). Figure 3 demonstrates the receiver operating characteristic analysis distribution of urinary NT-proBNP/creatinine ratios and birth weights. Urinary NT-proBNP/creatinine ratios demonstrated greater prognostic power in detecting pharmacological non-responsiveness than birth weight (area under the curve ¼ 0.60; 95% confidence interval, 0.294 to 0.906).
Finally, the logistic stepwise regression analysis, taking gestational age, gender and urinary NT-proBNP/creatinine ratio of DOL 2 into consideration, showed that urinary NT-proBNP (P ¼ 0.022) and gestational age (P<0.01) were independent variables for predicting pharmacological treatment.
Discussion
This is the first study relating urinary NT-proBNP, reported as NTproBNP/creatinine ratios, in very-low-birth weight infants to PDA closure. Urinary NT-proBNP/creatinine ratios peaked at 2 days of life, followed by a gradual decline until DOL 28. In infants who subsequently underwent treatment for a hemodynamically significant PDA, urinary NT-proBNP/creatinine ratios were significantly elevated on DOL 2 and 14 compared to controls (ventilated infants with no or only small PDA) and remained high until successful PDA closure. Urinary NT-proBNP/creatinine ratios at 14 days of life were highly predictive for non-responsiveness to pharmacological intervention for PDA closure.
Previous studies have explored urinary NT-proBNP levels in adult patients with cardiac failure. 18, 23 Ng et al. 23 compared urinary levels of NT-proBNP and plasma levels of NT-proBNP among 34 patients hospitalized for heart failure with 82 age-and sex-matched echocardiographically normal subjects. Urinary NTproBNP was reported to have a diagnostic accuracy comparable to that of plasma NT-proBNP for the diagnosis of heart failure. Cortes et al. 17 reported similar findings on both the diagnostic and the Urinary NT-proBNP and PDA C Czernik et al prognostic value of urinary NT-proBNP in 96 chronic heart failure patients. These studies demonstrated that NT-proBNP levels are detectable in the urine of patients with heart failure and useful in diagnosis and prognosis. Parallel measurements showed a good correlation between urinary and plasma NT-proBNP levels. The circulation and clearance mechanisms of NT-proBNP and BNP are not clearly understood. It is currently presumed that both peptides are secreted into the circulatory system in equal amounts, but differ in their clearance rates, as NT-proBNP is cleared only by a renal mechanism, while BNP is cleared by receptors, endopeptidases and the kidneys. The different concentrations of the circulating peptides are best explained by an increased rate of clearance for the active fragment BNP and by an increase in the number of receptors that remove BNP, but not the inactive fragment NT-proBNP. 24 These findings and the better stability of NT-proBNP over the more unstable BNP led us to investigate NT-proBNP in urine correcting for urinary creatinine.
In our study, the urinary levels followed a pattern quite similar to that seen in plasma samples.
Four studies have so far assessed the value of plasma NTproBNP concentrations for the early prediction of PDA. El-Khuffash et al. 16 reported a significantly elevated level of NT-proBNP at 48 h, but not at 12 h of age in preterm infants with hsPDA and a rapid decrease after successful PDA closure. Farombi-Oghuvbu et al.
14 studied serial plasma NT-proBNP levels on DOL 1, 3, 5 and 10 among 49 infants <34 weeks of gestation and found that the plasma NT-proBNP levels on days 3 and 5 but not on day 1 or 10 were significantly higher in infants with hsPDA compared to controls. Nuntnarumit et al. 12 demonstrated that DOL 2 plasma NT-proBNP levels in hsPDA premature infants were significantly higher than those of non-hsPDA infants, and that the levels declined rapidly within 24 to 48 h in infants who responded to indomethacin or ibuprofen therapy, whereas levels remained the same or decreased slightly in non-responders.Ramakrishnan et al.
11 investigated plasma NT-proBNP levels during the first week of life in 100 preterm infants (mean gestation 28.8 ± 2.9 weeks; mean birth weight 1224 ± 512 g) and found that plasma NTproBNP concentrations peaked on DOL 2 and 3 and then declined in the first week, but remained higher in preterm babies whose PDA required treatment.
Along with these studies, which found plasma NT-proBNP to be elevated with symptomatic PDA at the first days of life, 12-14 our study established the association between elevated urinary NTproBNP/creatinine ratios at the age of 2 and 14 days and hsPDA. Both these time points may be helpful in guiding PDA treatment decisions since optimal timing for hsPDA intervention ('early or delayed') remains an unresolved issue. [25] [26] [27] [28] [29] [30] There are a number of limitations to this study. First, sampling of urine was taken on DOL 2, 7, 14 and 28 and was not dependent on treatment of PDA. Second, we used spontaneous spot urine samples for testing. It would have been interesting to confirm our findings with a full 24-h urine sample; however, collecting urine over a period of 24 h in very preterm infants is tedious, especially for female infants. The Roche Elecsys cobas e 411 analyzer is configured to test plasma NT-proBNP samples, and this could have had an influence on the urine NT-proBNP determinations. However, the results obtained using the Roche Elecsys cobas e 411 analyzer to calculate urine NT-proBNP for diagnostic and prognostic purposes supports the accuracy of the measurements.
Assuming the urinary NT-proBNP/creatinine ratios reflect circulating plasma BNP, the data in this study suggest that circulating BNP may affect ductal patency. The biological actions of natriuretic peptides are mediated through membrane-bound natriuretic peptide receptors linked to a cyclic guanosine monophosphate-dependent signaling cascade, including natriuretic peptide receptor-A, which binds atrial natriuretic peptide and BNP. 31 Recombinant ANP has been show to reopen constricted ducts and maintains ductal patency in rats, 32 and we speculate that a similar mechanism might be operational also in humans.
The findings of this study suggest that serial urinary NT-proBNP measurements may be useful as a complementary tool to echocardiography or as an adjunct to clinical examination when regular echocardiographic expertise is not available. Urinary NTproBNP, a relatively simple non-invasive test, is a new candidate as a marker supporting a decision for PDA intervention and in guiding PDA treatment. Moreover, urine sampling would have a significant impact as it would replace the need for blood sampling to measure NT-proBNP and reduce the stressful and painful process of venipuncture in premature infants. This would reduce diagnostic blood loss in preterm infants, who have very limited blood reserves already, especially when repeated blood sampling becomes necessary. However, continuing research is needed to more accurately determine the levels of urinary of NT-proBNP that indicate a significant PDA and the best time point for this measurement.
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